Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired clonal hematopoietic stem cell disease. Clinical manifestations include intravascular hemolysis, renal dysfunction, fatigue, jaundice, pulmonary hypertension, and so on. Renal injury, as a clinical feature of PNH, is difficult to diagnose and is one of the causes of death in patients with PNH. This article reviews the progress in research on PNH combined with renal injury to improve clinicians’ understanding of renal injury in PNH patients, define and judge staging in a timely and accurate manner, enable patients to receive timely and appropriate treatment and reduce mortality.
HillmenPElebuteMKellyR, et al. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria. Am J Hematol2010; 85(8): 553–559.
2.
KimJSCheongJWMunYC, et al. Aplastic Anemia Working Party of the Korean Society of Hematology. Clinical implication of renal dysfunction during the clinical course in patients with paroxysmal nocturnal hemoglobinuria: a longitudinal analysis. Ann Hematol2019; 98(10): 2273–2281.
3.
JangJHKimJSYoonSS, et al. Predictive factors of mortality in population of patients with paroxysmal nocturnal hemoglobinuria (PNH): results from a Korean PNH Registry. J Korean Med Sci2016; 31(2): 214–221.
4.
NishimuraJMurakamiYKinoshitaT. Paroxysmal nocturnal hemoglobinuria: an acquired genetic disease. Am J Hematol1999; 62(3): 175–182.
5.
HillAKellyRJHillmenP. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood2013; 121: 4985–4996.
6.
SahinFOzkanMCMeteNG, et al. Multidisciplinary clinical management of paroxysmal nocturnal hemoglobinuria. Am J Blood Res2015; 5: 1–9.
7.
HillmenPMuusPRöthA, et al. Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol2013; 162: 62–73.
8.
AsimMIqbalZMujeebIB. Blue kidney in a pale patient—a case for a causal association between renal haemosiderosis in paroxysmal nocturnal haemoglobinuria and chronic kidney disease. NDT Plus2009; 2(5): 365–367.
9.
SchrezenmeierHRöthAAratenDJ, et al. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry. Ann Hematol2020; 99(7): 1505–1514.
10.
GautJPLiapisH. Acute kidney injury pathology and pathophysiology: a retrospective review. Clin Kidney J2020; 14(2): 526–536.
11.
ZagerRAGamelinLM. Pathogenetic mechanisms in experimental hemoglobinuric acute renal failure. Am J Physiol1989; 256(3 Pt 2): F446–F455.
12.
GembilloGSiligatoRCernaroV, et al. Complement inhibition therapy and dialytic strategies in paroxysmal nocturnal hemoglobinuria: the nephrologist’s opinion. J Clin Med2020; 9(5): 1261.
13.
MacedoÊSParente FilhoSLAProJDZ, et al. Renal involvement in paroxysmal nocturnal haemoglobinuria: a brief review of the literature. Rev Assoc Med Bras (1992)2018; 64(12): 1139–1146.
14.
RileyALRyanLMRothDA. Renal proximal tubular dysfunction and paroxysmal nocturnal hemoglobinuria. Am J Med1977; 62(1): 125–129.
15.
LodhiOUHSohailSHassanD. A rare case of paroxysmal nocturnal hemoglobinuria with bilateral renal vein thrombosis. Cureus2020; 12(6): e8806.
16.
RamRAdirajuKPGudithiS, et al. Renal manifestations in paroxysmal nocturnal hemoglobinuria. Indian J Nephrol2017; 27(4): 289–293.
17.
HsiaoPJWangSCWenMC, et al. Fanconi syndrome and CKD in a patient with paroxysmal nocturnal hemoglobinuria and hemosiderosis. Am J Kidney Dis2010; 55(1): e1–e5.
18.
MoumasEBridouxFLeroyF, et al. Fanconi syndrome and chronic kidney disease in paroxysmal nocturnal hemoglobinuria: effect of eculizumab therapy. Clin Nephrol2012; 78(4): 316–321.
19.
SaitoTFuryamaTOnoderaS, et al. Renal payment in patients with paroxysmal nocturnal hemoglobinuria. Tohoku J Exp Med1975; 116(3): 267–275.
20.
SheelvanthHVSayeedKAWhittierWA. Hemoglobinuric acute kidney injury in a patient with a kinked prosthetic aortic graft. Clin Nephrol2018; 89(4): 286–290.
21.
CharltonJRXuYWuT, et al. Magnetic resonance imaging accurately tracks kidney pathology and heterogeneity in the transition from acute kidney injury to chronic kidney disease. Kidney Int2021; 99(1): 173–185.
22.
PuriVGandhiASharmaS. Renal biopsy in paroxysmal nocturnal hemoglobinuria: an insight into the spectrum of morphologic changes. Indian J Nephrol2017; 27(4): 284–288.
HillmenPYoungNSSchubertJ, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med2006; 355(12):1233–1243.
25.
BrodskyRAYoungNSAntonioliE, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood2008; 111(4): 1840–1847.
26.
de FontbruneFSde LatourRP. Ten years of clinical experience with eculizumab in patients with paroxysmal nocturnal hemoglobinuria. Semin Hematol2018; 55(3): 124–129.
27.
PatriquinCJKissTCaplanS, et al. How we treat paroxysmal nocturnal hemoglobinuria: a consensus statement of the Canadian PNH Network and review of the national registry. Eur J Haematol2019; 102(1): 36–52.
28.
SchmidtCQSmithRJH. Protein therapeutics and their lessons: expect the unexpected when inhibiting the multi-protein cascade of the complement system. Immunol Rev2023; 313(1): 376–401.
29.
KelloNKhouryLEMarderG, et al. Secondary thrombotic microangiopathy in systemic lupus erythematosus and antiphospholipid syndrome, the role of complement and use of eculizumab: case series and review of literature. Semin Arthritis Rheum2019; 49(1): 74–83.
30.
NishimuraJYamamotoMHayashiS, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med2014; 370(7): 632–639.
31.
KanakuraYOhyashikiKShichishimaT, et al. Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial. Int J Hematol2013; 98(4): 406–416.
32.
VillegasANúñezRGayaA, et al. Presence of acute and chronic renal failure in patients with paroxysmal nocturnal hemoglobinuria: results of a retrospective analysis from the Spanish PNH Registry. Ann Hematol2017; 96(10): 1727–1733.
33.
KokorisSIGavriilakiEMiariA, et al. Renal involvement in paroxysmal nocturnal hemoglobinuria: an update on clinical features, pathophysiology and treatment. Hematology2018; 23(8): 558–566.
34.
VanwalleghemJZachéePKuypersD, et al. Renal transplantation for end-stage renal disease due to paroxysmal nocturnal haemoglobinuria. Nephrol Dial Transplant1998; 13(12): 3250–3252.
35.
WilkinsonTJMcAdams-DeMarcoMBennettPN, et al. Global Renal Exercise Network. Advances in exercise therapy in predialysis chronic kidney disease, hemodialysis, peritoneal dialysis, and kidney transplantation. Curr Opin Nephrol Hypertens2020; 29(5): 471–479.
